Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: SURVIVAL ; Germany ; MODEL ; HYBRIDIZATION ; PATIENT ; IMPACT ; INDUCTION ; treatment ; TRIAL ; IN-SITU ; cytogenetics ; AGE ; chemotherapy ; leukemia ; ABERRATIONS ; PROGNOSTIC-FACTORS ; HIGH-RISK ; PARAMETERS ; PROGNOSTIC-SIGNIFICANCE ; SELECTION ; ABNORMALITIES ; FLUORESCENCE ; ACUTE PROMYELOCYTIC LEUKEMIA ; POSTREMISSION THERAPY ; TRANS-RETINOIC ACID ; in situ hybridization ; PROGNOSTIC-FACTOR ; HIGH-DOSE CYTARABINE ; HISTONE ACETYLATION ; multivariate analysis ; SUBGROUPS ; COOPERATIVE-ONCOLOGY-GROUP ; CORE BINDING ; CUMULATIVE INCIDENCE ; GROUP-B
    Abstract: To assess the prognostic impact of cytogenetics in elderly patients with acute myeloid leukemia (AML) receiving intensive induction and consolidation treatment according to a single protocol specifically designed for patients above age 60, pretreatment samples from 361 patients registered for the AML HD98-B trial of the German-Austrian AML Study Group were analyzed by chromosome banding and fluorescence in situ hybridization, and cytogenetic findings were correlated with outcome. Using a proportional hazards model with backward selection, 3 prognostic subgroups were identified based on the influence of cytogenetic abnormalities on overall survival (OS): low-risk, t(15;17), and inv(16) in 25 of 361 patients (7%); standard-risk, normal karyotype, t(8;21), t(11q23), +8 within a noncomplex karyotype, and +11 within a noncomplex karyotype in 208 of 361 patients (58%); high-risk, all other aberrations in 128 of 361 patients (35%). On multivariate analysis, high-risk cytogenetics (hazard ratio [HR], 2.24) and age above 70 years (HR, 2.34) were independent prognostic factors affecting OS, and stratification according to these parameters demonstrated that a large subgroup of patients (55%), characterized by age 70 or older or high-risk cytogenetics, or both, had very unfavorable treatment results despite intensive chemotherapy. Thus, karyotype and age are major determinants of outcome in elderly patients with AML
    Type of Publication: Journal article published
    PubMed ID: 16840728
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: SURVIVAL ; Germany ; FOLLOW-UP ; RISK ; PATIENT ; IMPACT ; prognosis ; FREQUENCY ; TRIAL ; AGE ; MUTATION ; leukemia ; MUTATIONS ; diagnostics ; FREQUENT ; GLIOMAS ; acute myeloid leukemia ; ONCOLOGY ; ADULT ; ADULTS ; BRAIN-TUMORS ; overall survival ; MYELOID-LEUKEMIA ; PROGNOSTIC-FACTOR ; methods ; GENOTYPE ; RISK STRATIFICATION ; RECOMMENDATIONS ; CANCERS ; outcome ; IDH1 ; NADP(+)-DEPENDENT ISOCITRATE DEHYDROGENASE ; Genetic ; CODON 132 MUTATION ; GLIOBLASTOMAS ; RANGE ; ISOCITRATE DEHYDROGENASE ; GENETIC ALTERATIONS ; Follow up ; clinical oncology ; IDH1 mutation ; STRATIFICATION ; prognostic ; L-2-HYDROXYGLUTARIC ACIDURIA
    Abstract: Abstract PURPOSE: To analyze the frequency and prognostic impact of isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) mutations in acute myeloid leukemia (AML). PATIENTS AND METHODS: We studied 805 adults (age range, 16 to 60 years) with AML enrolled on German-Austrian AML Study Group (AMLSG) treatment trials AML HD98A and APL HD95 for mutations in exon 4 of IDH1 and IDH2. Patients were also studied for NPM1, FLT3, MLL, and CEBPA mutations. The median follow-up for survival was 6.3 years. RESULTS: IDH mutations were found in 129 patients (16.0%) -IDH1 in 61 patients (7.6%), and IDH2 in 70 patients (8.7%). Two patients had both IDH1 and IDH2 mutations. All but one IDH1 mutation caused substitutions of residue R132; IDH2 mutations caused changes of R140 (n = 48) or R172 (n = 22). IDH mutations were associated with older age (P 〈 .001; effect conferred by IDH2 only); lower WBC (P = .04); higher platelets (P 〈 .001); cytogenetically normal (CN) -AML (P〈 .001); and NPM1 mutations, in particular with the genotype of mutated NPM1 without FLT3 internal tandem duplication (ITD; P 〈 .001). In patients with CN-AML with the latter genotype, IDH mutations adversely impacted relapse-free survival (RFS; P = .02) and overall survival (P = .03), whereas outcome was not affected in patients with CN-AML who lacked this genotype. In CN-AML, multivariable analyses revealed a significant interaction between IDH mutation and the genotype of mutated NPM1 without FLT3-ITD (ie, the adverse impact of IDH mutation [RFS]; P = .046 was restricted to this patient subset). CONCLUSION: IDH1 and IDH2 mutations are recurring genetic changes in AML. They constitute a poor prognostic factor in CN-AML with mutated NPM1 without FLT3-ITD, which allows refined risk stratification of this AML subset.
    Type of Publication: Journal article published
    PubMed ID: 20567020
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...